Advertisement
As announced on February 26, 2007, the Phase 3 trial of glufosfamideshowed that the overall survival in patients with metastatic pancreatic cancerwho had relapsed after gemcitabine chemotherapy was 18% higher in theglufosfamide arm compared to those who received best supportive care (BSC),but the result did not reach statistical significance. Detailed analysis ofthe data from that study suggests that glufosfamide is active in certainsubgroups of patients. The Company believes that additional clinicalinvestigation of these subgroups is warranted. These data and subgroups willbe described during the oral presentation on September 27.
Advertisement
The following oral presentation will take place:
Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previouslytreated with gemcitabine: Results of a Phase 3 trial.
Gastrointestinal malignancies -- noncolorectal cancer, Room 111Thursday, September 27, 2007 at 10:15am
As announced on December 27, 2006, the response rate for the Phase 2glufosfamide plus gemcitabine front-line pancreatic cancer trial was 21%(including one unconfirmed partial response). The detailed results of thePhase 2 trial, including complete 12-month survival data, will be presentedduring a poster presentation on September 26.
The following poster presentation will take place:
Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma:Results of a Phase 2 trial.
Gastrointestinal malignancies -- noncolorectal cancer, Level 0Wednesday, September 26, 2007 from 9:00am to 12:00pm
A copy of the Phase 3 abstract will be available on the Threshold websiteon September 27. A copy of the Phase 2 poster and abstract will be availableon the website on September 26 athttp://investor.thresholdpharm.com/calendar.cfm.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery anddevelopment of small molecule therapeutics for the potential treatment ofcancer. By selectively targeting abnormally-proliferating tumor cells, theCompany's drug candidates are designed to be potentially more effective andless toxic to healthy tissues than conventional treatments. For additional
information, please visit our website (http://www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this pressrelease are forward-looking statements, including statements regardingThreshold's product candidates, and potential therapeutic uses and benefits ofour product candidates. These statements involve risks and uncertainties thatcan cause actual results to differ materially from those in suchforward-looking statements. Potential risks and uncertainties include, but arenot limited to, Threshold's ability to commence its anticipated clinicaltrials, the time and expense required to conduct such clinical trials andanalyze data, issues arising in the regulatory or manufacturing process andthe results of such clinical trials (including product safety issues andefficacy results). Further information regarding these and other risks isincluded under the heading "Risk Factors" in Threshold's Quarterly Report onForm 10-Q, which was filed with the Securities Exchange Commission onAugust 7, 2007 and is available from the SEC's website (http://www.sec.gov)and on our website (http://www.thresholdpharm.com) under the heading"Investors." We do not intend to update any forward-looking statement made inthis news release.Contact: Denise T. Powell Sr. Director, Corp
